Atricure, Inc. (ATRC) Stock Forecast Oct. 13, 2026
Analysis updated on Oct. 13, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Atricure, Inc. (ATRC) stock forecast summary
On Oct. 13, 2026, ATRC is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5379 stocks scored that day.
Atricure, Inc. is a mid-cap company with a market capitalization of $2.89B. It ranks number 24 by market capitalization among the 60 Surgical & Medical Instruments & Apparatus issuers in our coverage with a current forecast.
A per-ticker accuracy statistic for ATRC is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +4.5%, buy ≥ +3.4%, sell < +2.1%, strong sell < +0.9% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, ATRC included.
Follow ATRC freeATRC price chart and AI forecast
How ATRC ranks among 5379 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Atricure, Inc. (ATRC) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Surgical & Medical Instruments & Apparatus peers listed below that report each metric.
Reported net income does not reconcile with earnings per share and the share count, so net-income-based ratios are withheld.
Valuation & Market
| Metric | ATRC | Rank |
|---|---|---|
| Market Cap | $2.89B | 24/60 |
| P/B Ratio | 5.60x | 21/55 |
| EPS | $0.07 | – |
| Book Value/Share | $10.15 | – |
| Revenue/Share | $11.20 | – |
| FCF/Share | $1.04 | – |
Profitability & Margins
| Metric | ATRC | Rank |
|---|---|---|
| ROIC | 2.2% | 24/54 |
| Gross Margin | 76.3% | 13/52 |
| Operating Margin | 2.3% | 25/53 |
| EBT Margin | 2.1% | 23/53 |
| Tax Rate | 12.8% | – |
Financial Health
| Metric | ATRC | Rank |
|---|---|---|
| Current Ratio | 4.22x | 27/58 |
| Quick Ratio | 3.19x | 21/54 |
| D/E Ratio | 0.31x | 41/55 |
| Financial Leverage | 1.31x | 41/55 |
| Interest Coverage | 8.3x | 12/48 |
| Working Capital | $264M | 28/58 |
Cash Flow
| Metric | ATRC | Rank |
|---|---|---|
| Operating Cash Flow | $65M | 24/54 |
| Free Cash Flow | $53M | 19/48 |
| Capital Spending | -$12M | 24/48 |
| OCF Growth YoY | 78.2% | 4/32 |
| FCF Growth YoY | 110.0% | 4/24 |
| FCF/Sales | 9.3% | 19/47 |
| CapEx/Sales | 2.1% | 37/47 |
Operational Efficiency
| Metric | ATRC | Rank |
|---|---|---|
| Asset Turnover | 0.84x | 17/51 |
| Receivables Turnover | 7.1x | 16/50 |
| Inventory Turnover | 1.6x | 35/50 |
| Fixed Assets Turnover | 14.9x | 10/51 |
| Days Sales Outstanding | 51 days | 35/50 |
| Days Inventory | 227 days | 16/50 |
| Payables Period | 97 days | 10/45 |
| Cash Conversion Cycle | 181 days | 23/41 |
Income Statement
| Metric | ATRC | Rank |
|---|---|---|
| Total Revenue | $569M | 28/51 |
| Operating Income | $12M | 24/54 |
| R&D Expense | $98M | 16/52 |
| SG&A Expense | $324M | 25/53 |
| Cost of Goods Sold | $135M | 28/52 |
Dividend & Shareholder Information
| Metric | ATRC | Rank |
|---|---|---|
| Shares Outstanding | 51M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $346M | 51.1% of assets |
| Cash & Short-term Investments | $168M | 24.8% of assets |
| Accounts Receivable | $80M | 11.8% of assets |
| Inventory | $84M | 12.4% of assets |
| Total Liabilities | $160M | 23.7% of assets |
| Short-term Debt | $46M | 6.8% of assets |
ATRC quarterly financials and insider trading
Atricure, Inc. (ATRC) industry peers
Companies classified under the same SEC industry code as Atricure, Inc. (Surgical & Medical Instruments & Apparatus): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| ATRC Atricure, Inc. | ▶ | $2.89B |
| SYK Stryker Corp | ▼ | $108.38B |
| MMM 3m Co | ▼ | $83.94B |
| BSX Boston Scientific Corp | ▼ | $62.77B |
| BDX Becton Dickinson & Co | ▼ | $51.04B |
| MDLN Medline Inc. | ▼ | $46.94B |
| RMD Resmed Inc | ▼ | $33.91B |
| DXCM Dexcom Inc | ▶ | $32.42B |
| WST West Pharmaceutical Services Inc | ▼ | $26.17B |
| SOLV Solventum Corp | ▼ | $14.69B |
| BAX Baxter International Inc | ▶ | $12.87B |
| PEN Penumbra Inc | ▼ | $12.61B |
| GMED Globus Medical Inc | ▼ | $10.25B |
| GKOS Glaukos Corp | ▲ | $9.76B |
| PODD Insulet Corp | ▼ | $9.58B |
| STVN Stevanato Group S.P.A. | ▲ | $5.83B |
| HAE Haemonetics Corp | ▼ | $5.54B |
| TFX Teleflex Inc | ▼ | $5.27B |
| MMSI Merit Medical Systems Inc | ▼ | $5.26B |
| MMED Minimed Group, Inc. | ▶ | $5.18B |
| HTFL Heartflow, Inc. | ▲ | $4.38B |
| ICUI Icu Medical Inc/De | ▼ | $4.08B |
| IRTC Irhythm Holdings, Inc. | ▼ | $3.55B |
| PLSE Pulse Biosciences, Inc. | ▲ | $3.46B |
| UFPT Ufp Technologies Inc | ▶ | $2.28B |
| INSP Inspire Medical Systems, Inc. | ▶ | $1.99B |
| LMAT Lemaitre Vascular Inc | ▶ | $1.86B |
| ATEC Alphatec Holdings, Inc. | ▲ | $1.67B |
| NVCR Novocure Ltd | ▲ | $1.67B |
| KMTS Kestra Medical Technologies, Ltd. | ▲ | $1.61B |
| DRTS Alpha Tau Medical Ltd. | ▲ | $1.26B |
| TNDM Tandem Diabetes Care Inc | ▶ | $1.16B |
| IRMD Iradimed Corp | ▲ | $1.15B |
| BVS Bioventus Inc. | ▶ | $1.14B |
| PRCT Procept Biorobotics Corp | ▲ | $1.09B |
| IART Integra Lifesciences Holdings Corp | ▶ | $1.08B |
| AORT Artivion, Inc. | ▶ | $1.04B |
| SIBN Si-Bone, Inc. | ▶ | $882M |
| SGP Spyglass Pharma, Inc. | ▲ | $800M |
| BBNX Beta Bionics, Inc. | ▲ | $796M |
| MDXG Mimedx Group, Inc. | ▲ | $684M |
| KIDS Orthopediatrics Corp | ▶ | $573M |
| SSII Ss Innovations International, Inc. | ▶ | $511M |
| TCMD Tactile Systems Technology Inc | ▶ | $505M |
| BWAY Brainsway Ltd. | ▲ | $467M |
| SGHT Sight Sciences, Inc. | ▲ | $462M |
| CERS Cerus Corp | ▲ | $455M |
| ANGO Angiodynamics Inc | ▲ | $451M |
| NPCE Neuropace Inc | ▲ | $435M |
| RCEL Avita Medical, Inc. | ▲ | $413M |
| CARL Carlsmed, Inc. | ▲ | $395M |
| OFIX Orthofix Medical Inc. | ▼ | $377M |
| EMBC Embecta Corp. | ▶ | $351M |
| OBIO Orchestra Biomed Holdings, Inc. | ▲ | $344M |
| CLPT Clearpoint Neuro, Inc. | ▲ | $299M |
| MOBI Mobia Medical, Inc. | ▲ | $283M |
| ANIK Anika Therapeutics, Inc. | ▲ | $275M |
| TMCI Treace Medical Concepts, Inc. | ▲ | $267M |
| OSUR Orasure Technologies Inc | ▲ | $263M |
| PROF Profound Medical Corp. | ▲ | $256M |
Where ATRC sits on the market map
Atricure, Inc. (ATRC) stock news
Loading...
Atricure, Inc. (ATRC) stock forecast FAQ
What is the Atricure, Inc. (ATRC) stock forecast?
On Oct. 13, 2026, ATRC is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5379 stocks scored that day.
How accurate are Atricure, Inc. stock predictions?
A per-ticker accuracy statistic for ATRC is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Atricure, Inc. forecasts updated?
Atricure, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 13, 2026.
Which companies are Atricure, Inc.'s industry peers?
60 issuers in our coverage, ATRC included, share the SEC industry code Surgical & Medical Instruments & Apparatus. The largest are: Stryker Corp (SYK), 3m Co (MMM), Boston Scientific Corp (BSX), Becton Dickinson & Co (BDX), Medline Inc. (MDLN), Resmed Inc (RMD).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.